Abbott Announces New Partnerships and Programs To Advance Its Diversity in Clinical Trials Initiative

Abbott

• New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
• Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
• The new programs build on a successful first year of the multi-million-dollar corporate initiative

ABBOTT PARK, IL / ACCESSWIRE / May 11, 2023 / Abbott (NYSE:ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky.; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

"Clinical trials drive new, innovative tools to fight diseases, and overcoming barriers to access to clinical trials for under-represented communities is critical to improving health equity," said Andrea Wainer, executive vice president, Rapid and Molecular Diagnostics, and co-executive sponsor for the company's Diversity in Clinical Trials steering committee alongside Lisa Earnhardt, executive vice president of Medical Devices at Abbott. "Abbott has been focused on breaking down barriers and implementing new, sustainable partnerships and programs to drive even more diversity in our clinical trials and to ensure trials are offered in more places to reach underserved areas."

Improving Access Through New Clinical Research Models
Through a new five-year commitment, Abbott will work alongside the Institute for Health Equity at Norton Healthcare to build research program models that can be implemented by historically black colleges and universities (HBCUs) and clinics serving under-represented communities so they don't need to design and develop their own research programs from the ground up, which can be expensive and resource intensive.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 101,98$, was einem Rückgang von -2,53% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Morgan Stanley

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer